NuChem Therapeutics has wrapped up the acquisition of Amplia Pharmatek, a Quebec-based drug discovery and development contract research organization (CRO) with a focus on biology.

Based in Montreal, NuChem Therapeutics too is a drug discovery and development CRO. The company specializes in synthetic and medicinal chemistry services.

Amplia Pharmatek, on the other hand, is a service provider that specializes in discovery biology, in vivo pharmacology, pharmacokinetics, and toxicology.

Marc LeBel – president of NuChem Therapeutics said: “The combined forces of Amplia and NuChem will allow us to better serve our clients, our first priority. With our team of dedicated scientists and a brand new site built-to-suit, the future is bright.”

The two Canadian CROs will now form a growing team with 60 plus employees to provide a wide range of integrated services.

Zuomei Li – founder of Amplia Pharmatek said: “Our joint expertise will provide seamless services from lead molecule identification through the early development of drug candidates for multiple disease indications. The Amplia Team is thrilled to join the Nuchem family.”

  Amplia Pharmatek, Canada, Marc LeBel, NuChem Therapeutics, Pharma acquisition news, Zuomei Li